Characterizing the impact of a novel therapeutic on the infection strategy of pathogens

沙门氏菌感染是一个重大的公共卫生问题和疾病负担。的重要来源 感染通常是被污染肉和家禽、蛋和新鲜农产品。因此，控制 家禽产品中的沙门氏菌感染是减少人类感染的一种手段。虽然进步已经 在减少加工家禽中沙门氏菌污染的频率方面， 商业生产者在收获前生产设施中预防和/或消除这些病原体。 NovoBind畜牧治疗公司建议开发一种新型的基于抗体的治疗策略， 可以提供给商业种植者以防止和/或消除收获前的沙门氏菌病原体 家禽生产设施。目前，已经产生了新的沙门氏菌特异性抗体， 正在使用体外和体内方法测试它们的功效。这里提出的工作利用了 Michael Murphy博士在蛋白质生物化学，生物物理学和结构生物学领域的专业知识。这 该项目旨在：（1）优化NovoBind新型抗体和抗原的蛋白纯度和产量， 为了进行独特的概念验证实验，（2）测量抗体之间的结合强度 和抗原，以及（3）开始绘制最有希望的抗体/抗原组合之间的相互作用。 沙门氏菌选择性和高效抗体的开发将使加拿大和世界受益 通过减少人类感染和疾病、生命损失和治疗费用，减少人口。产生的收入 由NovoBind提供这一产品也将是一个经济刺激加拿大。

Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on the expertise of Dr. Michael Murphy in the fields of protein biochemistry, biophysics, and structural biology. This project proposes to: (1) optimize the protein purity and yields of NovoBind's novel antibodies and antigens in order to conduct unique proof of concept experiments, (2) measure the strength of binding between antibodies and antigens, and (3) begin to map the interaction between the most promising antibody/antigen combinations. The development of a Salmonella-selective and highly effective antibody would benefit Canadian and World populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada.